Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 18/20 | 0.55 |
| ▸ | MMP13 | P45452 | 18/20 | 0.55 |
| ▸ | MMP9 | P14780 | 15/20 | 0.55 |
| ▸ | MMP3 | P08254 | 11/20 | 0.55 |
| ▸ | MMP8 | P22894 | 11/20 | 0.55 |
| ▸ | MMP14 | P50281 | 11/20 | 0.53 |
| ▸ | MMP1 | P03956 | 4/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1464751 | 0.86 | MMP2 (0.57) | MMP2MMP13MMP9MMP3MMP8 | |
| SCHEMBL12827706 | 0.80 | ATM (0.52) | MMP13MMP9MMP1CYP3A4PKM | |
| SCHEMBL12827537 | 0.80 | MMP13 (0.53) | MMP2MMP13MMP9MMP3MMP8 | |
| SCHEMBL1464586 | 0.78 | MAPT (0.48) | MMP2MMP13MMP9MMP3MMP8 | |
| SCHEMBL12827677 | 0.75 | MMP2 (0.52) | MMP2MMP13MMP9MMP3MMP8 | |
| SCHEMBL1464400 | 0.74 | MMP13 (0.63) | MMP2MMP13MMP9MMP3MMP8 | |
| SCHEMBL1464610 | 0.73 | MMP2 (0.60) | MMP2MMP13MMP9MMP3MMP8 | |
| SCHEMBL1464255 | 0.73 | CNR2 (0.60) | MMP2MMP13MMP9MMP3MMP8 | |
| SCHEMBL12827674 | 0.73 | MAPT (0.47) | MMP2MMP13MMP9MMP3MMP8 | |
| SCHEMBL12827894 | 0.72 | MMP2 (0.45) | MMP2MMP13MMP9MMP3MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8299111-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-30 | — | — | US | disclosed |
| US-20110071127-A1 | Compounds Which Modulate the CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071127-A1 | Compounds Which Modulate the CB2 Receptor | CNR2, CNR1, OPRL1 | MMP2 2815/4885MMP13 2479/4885MMP9 3308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.